Teva Pharmaceutical Industries (TEVA) Stock Price Down 0%

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) were down 0% during mid-day trading on Thursday . The stock traded as low as $18.24 and last traded at $18.64. Approximately 48,777,184 shares changed hands during mid-day trading, an increase of 140% from the average daily volume of 20,284,979 shares. The stock had previously closed at $18.64.

Several analysts have issued reports on TEVA shares. Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, January 11th. Credit Suisse Group restated an “underperform” rating and issued a $8.00 target price (down from $14.00) on shares of Teva Pharmaceutical Industries in a report on Monday, November 6th. Morgan Stanley upgraded Teva Pharmaceutical Industries from an “underweight” rating to an “equal weight” rating and set a $18.00 target price for the company in a report on Friday, December 15th. Royal Bank of Canada set a $11.00 target price on Teva Pharmaceutical Industries and gave the company a “sell” rating in a report on Wednesday, November 29th. Finally, Cantor Fitzgerald set a $10.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, December 14th. Nine research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have assigned a buy rating to the company’s stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and a consensus target price of $21.54.

The stock has a market capitalization of $18,760.00, a price-to-earnings ratio of -3.18, a price-to-earnings-growth ratio of 1.48 and a beta of 0.59. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.76 by $0.17. The business had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 15.70% and a negative net margin of 24.35%. The company’s revenue was down 15.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.38 EPS. research analysts anticipate that Teva Pharmaceutical Industries Ltd will post 3.73 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Northern Cross LLC boosted its holdings in Teva Pharmaceutical Industries by 14.0% during the 2nd quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after acquiring an additional 2,184,172 shares during the period. Schroder Investment Management Group boosted its holdings in Teva Pharmaceutical Industries by 22.7% during the 3rd quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock valued at $106,290,000 after acquiring an additional 1,147,683 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Teva Pharmaceutical Industries by 4.5% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,035,644 shares of the company’s stock valued at $106,271,000 after acquiring an additional 259,891 shares during the period. State Street Corp boosted its holdings in Teva Pharmaceutical Industries by 5.1% during the 2nd quarter. State Street Corp now owns 4,763,692 shares of the company’s stock valued at $158,254,000 after acquiring an additional 232,924 shares during the period. Finally, Macquarie Group Ltd. raised its position in Teva Pharmaceutical Industries by 350.3% in the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock valued at $77,587,000 after purchasing an additional 3,429,448 shares in the last quarter. Institutional investors own 51.99% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://sportsperspectives.com/2018/02/09/teva-pharmaceutical-industries-teva-stock-price-down-0.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply